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Progression of hippocampal shape and volume abnormalities has been described in psy-
chotic disorders such as schizophrenia. However it is unclear how specific antipsychotic
medications influence the development of hippocampal structure. We conducted a longitu-
dinal, randomized, controlled, multisite, double-blind study involving 14 academic medical
centers (United States 11, Canada 1, Netherlands 1, and England 1). One hundred thirty-four
first-episode psychosis patients (receiving either haloperidol [HAL] or olanzapine [OLZ]) and
51 healthy controls were followed for up to 104 weeks using magnetic resonance imag-
ing and large-deformation high-dimensional brain mapping of the hippocampus. Changes
in hippocampal volume and shape metrics (i.e., percentage of negative surface vertex
slopes, and surface deformation) were evaluated. Mixed-models analysis did not show
a significant group-by-time interaction for hippocampal volume. However, the cumulative
distribution function of hippocampal surface vertex slopes showed a notable left shift with
HAL treatment compared to OLZ treatment and to controls. OLZ treatment was associated
with a significantly lower percentage of “large magnitude” negative surface vertex slopes
compared to HAL treatment (p=0.004). Surface deformation maps however did not local-
ize any hippocampal regions that differentially contracted over time with OLZ treatment,
after FDR correction. These results indicate that surface analysis provides supplementary
information to volumetry in detecting differential treatment effects of the hippocampus.
Our results suggest that OLZ is associated with less longitudinal hippocampal surface
deformation than HAL, however the hippocampal regions affected appear to be variable
across patients.
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INTRODUCTION
Abnormalities of the hippocampus are widely implicated as con-
tributing to the pathophysiology of schizophrenia. The hippocam-
pus is involved in encoding explicit long-term memory, both
episodic and semantic, which are often found to be dysfunctional
in patients with psychotic disorders (Goldberg et al., 1998; Boyer
et al., 2007). Structural abnormalities of the hippocampus have
also been noted in psychosis (Mamah et al., 2009). For example,
the majority of in vivo imaging studies show hippocampal vol-
ume reductions in schizophrenia patients compared to healthy
controls (Lawrie and Abukmeil, 1998; Nelson et al., 1998; Wright
et al., 2000; Honea et al., 2005).
Computational image analysis methods have several advan-
tages over traditional volumetric approaches in evaluating brain
structures. They can isolate abnormalities locally within a struc-
ture and identify more subtle abnormalities potentially associated
with neuropathy. Computerized methods have been used to char-
acterize surface features of regions of interest in three-dimensional
space (Thompson et al., 2000; Ashburner et al., 2003). Some
of these methods have found regional alterations in hippocam-
pal shape, with anterior-lateral regions affected, in schizophrenia
(Haller et al., 1996; Csernansky et al., 1998, 2002; Wang et al., 2001;
Mamah et al., 2010). Other shape analysis tools however found
abnormalities in other hippocampal regions (Shenton et al., 2002;
Styner et al., 2004). In spite of differences in results between lab-
oratories, the shape metrics reported by the various groups show
promise for clarifying the nature of hippocampal morphological
changes in schizophrenia.
Several lines of evidence suggest a progressive neuropathologic
process that underlies the deteriorating clinical course of schizo-
phrenia (Loebel et al., 1992; Davis, 1999; Lieberman, 1999). Lon-
gitudinal imaging studies of the hippocampus in schizophrenia
have often revealed progression of volume decrease in the hip-
pocampus (Velakoulis et al., 2000; Szeszko et al., 2002; Joyal et al.,
2003). UsingLarge-DeformationHigh-Dimensional BrainMapping
(HDBM-LD), our group found significantly abnormal hippocam-
pal shape change (over 2 years) in schizophrenia in the absence of
volumetric abnormalities (Wang et al., 2008), suggesting that shape
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analysis is complementary to volumetry in assessing longitudinal
changes.
It remains unclear to what degree antipsychotic treatment con-
founds longitudinal imaging studies of hippocampal morphology
in patients. Preclinical studies have suggested that specific atypical
antipsychotic drugs may have pharmacologic properties that could
produce neurotrophic, neurogenetic, or neuroprotective effects
(Wakade et al., 2002; Bai et al., 2003; Halim et al., 2004). A limi-
tation of the existing studies on effects of antipsychotics on brain
structure is that they have often investigated patients treated for
many years, with different types of antipsychotic drugs. This makes
it difficult to disentangle which brain changes are due to a specific
class of antipsychotics, and which are due to the illness and its
progression (Dazzan and Murray, 1999). Therefore, these ques-
tions can be better addressed by investigating subjects at the initial
stages of psychosis, when treatment would have occurred for only
a short time. The older, “typical” antipsychotics, such as HAL,
act on the dopaminergic system by blocking the dopamine type
2 (D2) receptors in mesolimbic areas (Carlsson, 1978). Newer,
“atypical” antispychotics have lower affinity and occupancy for
the dopaminergic receptors, and a high degree of occupancy of
the serotoninergic receptors 5-HT2A (Meltzer et al., 1999). Dif-
ferences in receptor affinities between the two general drug classes
have been linked to greater effectiveness of atypical antipsychotics
on cognitive dysfunction and negative symptoms in schizophre-
nia patients (Abdul-Monim et al., 2003; Karow et al., 2006; Meltzer
and Sumiyoshi, 2008; He et al., 2009), although other studies have
showed no such advantages (Rollnik et al., 2002; White et al.,
2006).
In patients with first-episode psychosis, Lieberman et al. (2005)
found that HAL-treated patients exhibited significant decreases
in cortical gray matter volume, whereas patients treated with the
atypical antipsychotic olanzapine (OLZ) did not. In this study, we
investigated the longitudinal effects of OLZ and HAL treatment on
hippocampal volume and shape, using most of the same subjects
previously studied (Lieberman et al., 2005). We hypothesized that
OLZ would lead to less global and regional hippocampal volume
decrease compared to HAL.
MATERIALS AND METHODS
This longitudinal study was conducted at 14 academic medical
centers (11 in the United States, 1 in Canada, 1 in the Netherlands,
and 1 in England; Lieberman et al., 2005).
PARTICIPANTS
Table 1 shows participant profiles in each group. One hundred
thirty-four first-episode psychotic patients (PSY) and 51 healthy
controls (CON) were included in the study. Patients included those
who presented for clinical services. Inclusion criteria included:
(1) diagnosis of schizophrenia, schizophreniform, or schizoaf-
fective disorder according to DSM-IV criteria (as assessed with
the Structured Clinical Interview for DSM-IV, Research Version
(First et al., 2002), (2) age 16–40 years, (3) onset of psychotic
symptoms before age 35 years, and (4) premorbid IQ of 70
or more. Exclusion criteria included (1) previous antipsychotic
drug treatment of more than 16 cumulative weeks, or treatment
with clozapine at any time (2) current substance dependence
(except caffeine and nicotine) within 1 month before study entry,
and (3) treatment with anticonvulsants, benzodiazepines (except
as allowed for agitation and control of extrapyramidal symp-
toms), antidepressants, psychostimulants, or other antipsychotic
drugs at study entry. Healthy volunteers matched to the patients’
demographic characteristics were ascertained from respondents to
advertisements.
STUDY DESIGN AND PROCEDURES
Patients were randomized to double-blind treatment with OLZ,
5–20 mg/day, or HAL, 2–20 mg/day, for up to 104 weeks. Permit-
ted concomitant medications (for no more than 21 days) included
chloral hydrate, lorazepam, or diazepam, for the management of
agitation, general behavior disturbances, and/or insomnia. If clin-
ically important extrapyramidal symptoms emerged, anticholin-
ergic medication was also permitted. Antidepressants (except flu-
oxetine hydrochloride) and/or mood stabilizers were not allowed
in the first 12 weeks of the study.
IMAGE ACQUISITION AND PREPROCESSING
Scans used for the study included the majority of those assessed in a
prior longitudinal study of brain volume (Lieberman et al., 2005).
Briefly, participants were assessed using MRI at weeks 0 (baseline),
12, 24, 52, and 104. All MRI studies were performed on 1.5T MRI
systems. Six of the eight imaging sites used Signa scanners (General
Electric Co., Milwaukee, WI, USA), and two sites used a Gyroscan
scanner (Philips Medical Systems, Best, the Netherlands). The
imaging protocol included 3-dimensional T1-weighted, inversion
recovery-prepared spoiled gradient-recalled acquisition in steady
state images (0.94 mm× 0.94 mm× 1.50 mm, axial direction) and
contiguous proton density and T2-weighted fast spin-echo images
(0.94 mm× 0.94 mm× 3.00 mm, axial slicing direction). Qual-
ity control scans were performed twice a month on each MRI
system with standardized imaging phantoms. Rigorous standard-
ization and quality control procedures were used and reliability
of the measurements across sites was established and maintained
throughout the study (Styner et al., 2002).
SURFACE GENERATION
Hippocampal surface generation of baseline scans was done by
HDBM-LD from a neuroanatomical template (Haller et al., 1997;
Miller et al., 1997a; Csernansky et al., 2004). An MR scan collected
from a healthy comparison subject was used to construct a neu-
roanatomical template (Csernansky et al., 1998, 2002; Wang et al.,
2008). In the construction of this template the right hippocampus
was manually outlined by expert consensus using atlas (Mai et al.,
1997) guidelines. A set of landmarks was developed for placement
within the hippocampus in MR scans of the template and each
study subject. Transformation of the template MR scan onto the
MR scan of study subjects (“subject scan”) occurred in two steps.
First, the template scan was coarsely aligned to the left and right
sides of each subject scan using the landmarks. Second, HDBM-
LD was used to determine the transformation between template
and subject scan (Haller et al., 1997). To derive a surface for each
hippocampus, a triangulated graph was first superimposed onto
the surface of the hippocampus in the right hemisphere of the
template scan. This surface was then carried along as the template
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Table 1 | Demographic and clinical profiles.
Characteristics Control n=51 Olanzapine n=67 Haloperidol n=67 p-Value
Olz vs. Hal Scz vs. Con
Age 25.0 (3.9) 23.7 (4.6) 24.3 (4.7) 0.46 0.16
Gender – N (%)
Female 16 (31.4) 13 (19.4) 8 (11.9) 0.23 0.02*
Male 35 (68.6) 54 (80.6) 59 (88.1)
Race – N (%)
African American 15 (29.4) 23 (34.3) 29 (47.5) 0.44 0.23
Asian 0 1 (1.5) 0
Caucasian 30 (58.8) 36 (53.7) 28 (45.9)
East Asian 4 (7.8) 1 (1.5) 1 (1.6)
Hispanic 1 (2.0) 3 (4.5) 3 (4.9)
Other 1 (2.0) 3 (4.5) 0
Illness duration (weeks) – 57.1 (52.0) 78.4 (63.0) 0.034* n/a
Diagnosis – N (%)
Schizophrenia, disorganized – 3 (4.4) 2 (3.0) 0.48 n/a
Schizophrenia, paranoid – 25 (37.3) 31 (49.3)
Schizophrenia, undifferentiated – 11 (16.4) 15 (22.4)
Schizophreniform disorder – 20 (29.9) 15 (22.4)
Schizoaffective disorder – 8 (11.9) 4 (6.0)
Time point – N (% of week 0)
Baseline (week 0) 51 (100) 67 (100) 67 (100) n/a n/a
Week 12 47 (92.2) 60 (89.6) 61 (91.0) n/a n/a
Week 24 – 56 (83.6) 40 (59.7) n/a n/a
Week 52 43 (84.3) 37 (55.2) 30 (44.8) n/a n/a
Week 104 – 24 (35.8) 11 (16.4) n/a n/a
Values are means (standard deviation) unless stated otherwise.
*Statistically significant (p<0.05) between group differences.
n/a=not applicable.
scan was transformed to match the left and right sides of each
of the subject scans. The reliability of this process is comparable
to manual outlining by experts for defining the neuroanatomical
boundaries of the hippocampus (Haller et al., 1997; Csernan-
sky et al., 1998). To map the surfaces at follow-up, baseline and
follow-up scans were first registered using a nine-parameter affine
transformation to adjust for changes in head position and scanner-
drift (Freeborough et al., 1996). Next, HDBM-LD was used in
neuroanatomic regions immediately surrounding the structures
of interest, at twice the native-scan resolution (Wang et al., 2008).
Atlas based segmentation of total cortical gray matter (Gout-
tard et al., 2007) were done to allow for cortical volume to be used
as a covariate in baseline hippocampal volume analyses.
BASELINE ANALYSIS OF HIPPOCAMPAL VOLUME AND SHAPE
Left and right baseline volumes were entered into a repeated-
measures analysis of variance (RM-ANOVA) model, with group
as the main effect, and hemisphere as a repeated factor.
To quantify surface shape, we first applied principal compo-
nents analysis (PCA) to the baseline right and left surfaces for
dimensionality reduction (Csernansky et al., 2002; Wang et al.,
2008). The first 20 principal components (PC) accounted for more
than 90% of total surface variance. To evaluate baseline differences
in overall hippocampal shape, the 20 PC scores were entered into
a RM-MANOVA with diagnostic group as the main effect, and
hemisphere as a repeated factor.
LONGITUDINAL ANALYSIS OF HIPPOCAMPAL VOLUME AND SHAPE
To evaluate longitudinal effects on hippocampus volume, for each
subject, slopes of volume change over the time were calculated
using linear least squares across all available time points (see
Table 1 for distribution of available time points). Slopes were then
compared using RM-ANOVA with hemisphere as a repeated fac-
tor. As a secondary longitudinal analysis, mixed-models analyses
of hippocampal volume with time as within subjects factor were
performed.
Evaluation of the longitudinal effect on hippocampal shape
was done using the percentage of negative surface vertex slopes and
the percentage of “large magnitude” surface vertex slopes. These
measures were computed across vertices individually in each sub-
ject, using the slope map for each subject. Large magnitude sur-
face vertex slopes (i.e., “very negative slopes” and “very positive
slopes”) were evaluated since these may differ between groups,
despite a similar proportion of negative slopes. “Very negative
slopes” were defined as slopes with values more negative than
1 SD below the mean slope of controls. “Very positive slopes” had
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values more positive that 1 SD above the mean slope of controls.
These measures were then were compared across subjects using
ANOVA, since the distribution of values approximated normality
(Shapiro–Wilk test, p> 0.05).
To visualize potential regional effects, slope maps were com-
puted on the hippocampi of individual subjects, using slope values
at each surface vertex (13,222 over both hippocampi). Values at
each vertex were then averaged across subjects to generate mean
group hippocampal slope maps, which were compared using the
Mann–WhitneyU test. To correct for multiple comparisons across
the multiple hippocampal surface vertices, false discovery rate
(FDR) thresholding was applied in which the p-value maps were
thresholded to yield an FDR of 5% (i.e., q= 0.05). For visualiza-
tion of the mean slope maps, slope directions were color-coded,
with warmer (i.e., red-orange) colors depicting positive slopes, and
cooler colors (i.e., purple-blue) depicting negative slopes.
RESULTS
BASELINE VOLUME ANALYSES
At baseline, volume in mm3 (and standard deviation) of
the left hippocampus was 2,252 (304) and right hippocam-
pus was 2,696 (374) in psychotic subjects (PSY), while left
hippocampus was 2,528 (318) and right hippocampus was
3,010 (313) in controls. There was a significant group effect
[F(1,183)= 33.2, p< 0.0001]. Across all subjects, there was a
significant effect of hemisphere [right> left; F(1,183)= 531.5,
p< 0.0001], but no significant group-by-hemisphere interaction.
Results of group comparisons were similar after controlling for
gender [F(1,182)= 40.8, p< 0.0001] or total gray matter vol-
ume [F(1,182)= 41.2, p< 0.0001]. Additionally controlling for
illness duration did not affect volume comparisons. Baseline com-
parisons of the hippocampal volume in PSY did not show any
significant differences between the groups that were subsequently
treated with OLZ vs. HAL on the left (p= 0.99) or right (p= 0.65).
At baseline, volume (mm3) of total brain gray matter was
691,758 (72,941) in PSY and 705,594 (69,608) in controls. There
was no significant group effect of total gray matter [F(1,183)= 1.4;
p= 0.24], however correction for gender resulted in a significant
group effect [CON>PSY; F(1,182)= 5.7; p= 0.02].
BASELINE HIPPOCAMPAL SHAPE ANALYSES
A comparison of hippocampal shape in PSY and CON done
using a MANOVA with the first 20 shape principal compo-
nent scores (eigenvectors) showed significant differences on the
left (Wilks= 0.69; p< 0.0001) and on the right (Wilks= 0.66;
p< 0.0001). Controlling for gender or illness duration did not
change results of the analysis. Surface maps depicting hippocam-
pal shape in PSY are shown in Figure 1. Visual observation shows
inward deformation particularly of the head and lateral regions
(extending into the tail) of the hippocampus in PSY, compared to
CON. There was also a region of slight outward deformation of
the postero-dorsal surface of the left hippocampus tail in PSY.
LONGITUDINAL HIPPOCAMPAL VOLUME ANALYSES
Slope comparisons
Left hippocampal volume slopes in mm3 per week were −0.80
(2.8) in OLZ,−1.94 (5.4) in HAL, and−0.45 (1.8) in CON. Right
hippocampal slopes were−0.93 (2.0) in OLZ,−1.58 (6.3) in HAL,
and −0.47 (2.1) in CON. There was no significant overall group
effect [F(2,182)= 1.9, p= 0.15], hemisphere effect (p= 0.7), or
group-by-hemisphere interaction (p= 0.5).
Mixed-models analysis
Longitudinal analysis comparing CON, OLZ, and HAL on hip-
pocampal volume showed a significant time effect of the hip-
pocampus on the left [F(4,399)= 9.8, p< 0.0001] and right
[F(4,399)= 13.5, p< 0.0001] across groups, but no significant
group-by-time interaction (left: p= 0.76; right: p= 0.56).
LONGITUDINAL SHAPE ANALYSES
Cumulative distribution of surface vertex slopes
Figure 2 shows the cumulative distribution functions of the mean
slope map for each subject group. (The distribution is across
the 13,222 hippocampal surface vertices). As can be seen in this
Figure, the distributions of surface vertex slopes in HAL were
shifted toward more negative values compared to CON, while OLZ
had an intermediate distribution. Differences between HAL and
CON also appeared to be greater at more negative slopes. The
group averages of the vertex slopes (averaged across all vertices, in
mm/year) were−0.011 (0.057) for CON,−0.022 (0.057) for OLZ,
and−0.066 (0.077) for HAL.
We used two approaches to quantify this effect. First, we
examined the percentage of negative slopes in each group (see
Table 2), using an ANOVA with group, and hemisphere as fac-
tors. This ANOVA did not show significant group differences
[F(2,182)= 2.2, p= 0.12], and there were no significant hemi-
sphere effects or group x hemisphere interactions. Second, we
then evaluated the percentage of hippocampal surface vertex
slopes more negative in magnitude than 1 standard deviation
(SD) below or above the mean slope in controls (see Table 2).
This ANOVA showed a highly significant main effect of group
[F(2,182)= 6.5, p= 0.0019]. Post hoc analyses showed significant
differences between HAL vs. OLZ (p= 0.004), and HAL vs. CON
(p= 0.003), but no significant differences between OLZ vs. CON
(p= 0.8). There was no significant effect of hemisphere and no
significant group× hemisphere interaction.
Surface map generation
Visual representations of hippocampus surface vertex slopes are
depicted in Figure 3. HAL treatment was associated with large con-
fluent regions of negative longitudinal slopes throughout the hip-
pocampal body, head, and tail. In both CON and OLZ hippocampi,
there were fewer negative and more positive slope regions than in
HAL hippocampi. In addition, negative slopes appeared lesser in
magnitude in CON and OLZ compared to HAL. There were no sta-
tistically significant surface vertex slope differences between HAL
and OLZ after FDR correction at the 0.05 level.
DISCUSSION
Our study utilized shape analysis methodology to evaluate the
hippocampus in young patients at a very early stage of psy-
chotic illness. We found reduced hippocampal volume in patients,
consistent with most previous findings of decreased size of the
hippocampus in schizophrenia (Velakoulis et al., 1999, 2006; Gur
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FIGURE 1 | Hippocampal surface maps showing baseline structural
differences between first-episode psychosis patients and controls.
Hippocampal surface generation of baseline scans was done by
high-dimensional brain mapping (HDBM-LD) from a neuroanatomical template
(see Materials and Methods). Groups were compared at each of 13,222
corresponding vertices on the hippocampal surface. Top row: structural
differences are shown using a continuous color-coded scale. Purple/blue
shading denotes regions of inward surface displacement (i.e., surface
contraction) in first-episode psychosis patients compared to controls.
Red/orange shading denotes regions of outward displacement (i.e., surface
expansion). Bottom row: structural differences shown using a color-coded
scale thresholded at statistical significance. Purple regions show statistically
significant (p<0.05) inward displacement in psychotic patients compared to
controls. Red regions show statistically significant (p< 0.05) outward
displacement in psychotic patients compared to controls. Green regions
indicate statistically similar group values. Surface vertex differences are
thresholded at a false discovery rate (FDR) of 5% (i.e., q = 0.05) applied to
Mann–Whitney U test based p-values.
et al., 2000), and in first-episode psychosis (Whitworth et al., 1998;
Sumich et al., 2002; Steen et al., 2006; Vita and de Peri, 2007;
Ebdrup et al., 2010). Compared to controls, we found that psy-
chotic patients had hippocampal surface contraction at baseline
predominantly on areas of the anterior hippocampus and lateral
parts of its body and tail. The pattern of this hippocampal defor-
mation was similar to what we previously found in chronic schiz-
ophrenia patients using identical mapping methodology (Cser-
nansky et al., 1998, 2002). Inward deformations along the lateral
edges extending toward the tail and an outward deformation on
the left dorsal tail, which were observed in our current study, were
however not present in our previous chronic patients (Csernansky
et al., 1998, 2002), which may suggest greater specificity of anterior
hippocampal deformity with more chronic illness.
The clinical significance of regional abnormality within the
hippocampus in schizophrenia may be related to regional asso-
ciations with specific brain regions influencing cognitive func-
tion. Functionally, heightened CA3 activity in schizophrenia may
generate exaggerated pattern completion memory functions and
enhance the production of incorrect associations, which would
then produce memories with psychotic content (Corlett et al.,
2009; Tamminga et al., 2010). CA3 volumetric enlargement may
be supported by our current findings, which showed hippocampal
surface expansion in an area of the surface consistent with pos-
terior CA2-CA4 plus dentate gyrus subfields (Csernansky et al.,
2005; Wang et al., 2006). We also found that in the hippocam-
pus of those with psychotic disorders, surface contractions occur
mainly in regions corresponding to CA1 subfield (located in the
anterior and lateral hippocampus) and to a lesser degree, anterior
subiculum (Csernansky et al., 2005; Wang et al., 2006). Together,
these findings raise the possibility that in first-episode psychosis,
reduced nerve fibers, and connections may be present within the
CA1 subfield, and the opposite effect to a smaller degree in other
regions, possibly the CA3 subfield. Recent human studies have also
localized abnormal neuronal activity to the CA1 region in schizo-
phrenia patients and found this to be associated with psychotic
symptom severity and a predictor of conversion to syndromal
psychosis in prodromal subjects (Schobel et al., 2009).
We found a significant progressive hippocampal volume
decrease over time in both first-episode psychosis patients and
controls. However, the differences in the rate of progression did not
reach statistical significance between groups, consistent with pre-
vious studies in first-episode psychosis (DeLisi et al., 1997; Wood
et al., 2001; Whitworth et al., 2005). Most longitudinal studies
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FIGURE 2 | Cumulative distribution functions of hippocampal surface
vertices. Group distributions of mean slope (mm/year) across the 13,222
hippocampal surface vertices (left and right combined) are shown. Slopes
were calculated using all available visits (up to a maximum follow-up of
104 weeks). Black=Healthy controls. Red=Olanzapine-treated patients.
Blue=Haloperidol-treated patients.
in chronic schizophrenia however indicate progression of volume
decrease in the hippocampus (Velakoulis et al., 2000; Szeszko et al.,
2002; Joyal et al., 2003), or the anterior hippocampus (Lieber-
man et al., 2001), although negative results have also been found
(Degreef et al., 1991). Thus, our findings may indicate that at the
early stage of schizophrenia the rate of progression of hippocam-
pal abnormality may be slower than at later stages of illness, or
that volume changes have already occurred (Lawrie et al., 1999).
Our analysis of longitudinal shape change suggests that vol-
ume loss does not occur universally across the hippocampus. The
surface map findings showed patchy areas of surface contraction
or expansion. These findings are plausible as prior post-mortem
studies of schizophrenia have found the pathology to be focal
and much less evenly distributed throughout the medial tempo-
ral lobe structures (Harrison, 2004; Heckers and Konradi, 2010).
In addition, given the anatomy of the hippocampus and its com-
position by distinct cytoarchitectural regions it stands to reason
that different areas would be affected, by different degrees and
sequence (Mai et al., 1997). Visual observation of surface maps
suggested that HAL have larger regions of longitudinal surface
contractions than either OLZ or controls. A larger region of sur-
face contraction with HAL was supported by a left shift of the
cumulative distribution of the hippocampal vertex slopes in the
HAL group compared to other groups. Differences in the per-
centage of negative slopes between HAL and OLZ, however did
not reach significance. However, when the percentages of large
magnitude slopes were compared, significant group differences
were observed, with HAL having more large magnitude negative
slopes. This indicates that with both OLZ and HAL treatment var-
ious regions of the hippocampus contract over time, however the
magnitudes of these surface contractions differ.
Olanzapine-associated effects could reflect a therapeutic effect
of treatment (in preventing a disease-associated volume loss)
and/or a neuroplastic adaptation to chronic treatment, such as
has been seen in the caudate and lenticular nuclei (Chakos et al.,
1994, 1998; Roberts et al., 1995) and in prefrontal cortex (Selemon
and Goldman-Rakic, 1999). Antipsychotic drugs have been found
to have a variety of effects on brain structure and volume both pro-
tective or enhancing (Konradi and Heckers, 2001) and associated
with volume reduction (Dorph-Petersen et al., 2005; Ho et al.,
2011). Specific atypical antipsychotic drugs (particular clozap-
ine and OLZ) have been reported to have various actions that
could enhance cellular resilience and ameliorate the pathophysi-
ology of schizophrenia (Lieberman et al., 2008). These include the
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Table 2 | Statistical analysis of surface point slopes across groups.
Analysis Group value (SD) F or H p
CON OLZ HAL
PERCENT NEGATIVE SLOPE:
% Negative Surface Slopesa
Left hippocampus 52.4 (8.3) 53.9 (10.2) 56.6 (12.2) 2.38 0.10
Right hippocampus 52.2 (7.2) 53.5 (10.0) 55.1 (11.6) 1.28 0.28
% Surface Slopes Negative of 1 SD Below Meanb
Left hippocampus 35.8 (10.2) 35.0 (16.0) 43.3 (16.1) 6.25 0.002*
Right hippocampus 35.4 (8.2) 35.0 (15.1) 42.1 (15.1) 5.59 0.004*
% Surface Slopes Positive of 1 SD Above Meanc
Left hippocampus 36.1 (9.1) 32.7 (12.8) 34.1 (12.7) 1.15 0.32
Right hippocampus 36.5 (8.2) 33.3 (13.0) 35.7 (12.1) 1.26 0.29
ANOVA used for analysis of “percent negative slope” comparisons across the three groups. Percent negative slopes’ are given in percentages (standard deviation).
aPercentage of hippocampal surface points with longitudinal slope values <0.
bPercentage of hippocampal surface points with longitudinal slope values more negative than 1 standard deviation below the average mean surface point value in left
and right hemisphere of controls (−0.06798 mm/year).
cPercentage of hippocampal surface points with longitudinal slope values more positive than 1 standard deviation above the average mean surface point value in left
and right hemisphere of controls (0.04680 mm/year).
*Statistically significant (p<0.05) after correcting for multiple comparisons.
FIGURE 3 | Hippocampal surface maps showing progression of
surface displacement. Mean slope values (depicting longitudinal
structural change over a maximum period of 104 weeks) at each
hippocampal surface vertex were calculated in each group. Slope values
are color-coded, with purple/blue regions denoting regions of longitudinal
surface contraction and red/orange regions denoting regions of
longitudinal surface expansion. Surface maps are thresholded between
slope values of ±0.1 mm/year.
antagonism of the effects of N -methyl-d-aspartate receptor antag-
onists (Olney and Farber, 1995; Duncan et al., 2000), increased
expression of tropic factors (Bai et al., 2003; Fumagalli et al., 2003;
Marx et al., 2003), and stimulation of neurogenesis (Wakade et al.,
2002; Halim et al., 2004). The effects of antipsychotics may also
result from alterations in blood flow and metabolism within the
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hippocampus as opposed to neuronal changes (Miller et al., 1997b;
Cohen et al., 1999; Molina et al., 2003; Lahti et al., 2004). As the
hippocampal surface vertex slopes of untreated psychotic patients
are unknown, it is unclear if HAL prevents surface contraction
to any degree. However, hippocampal volume loss has been asso-
ciated with quetiapine in first-episode psychosis over 6 months,
especially at higher doses (Ebdrup et al., 2010).
There are potential limitations to our study findings. Despite
the highly significant group difference in the number of large neg-
ative hippocampal surface vertex slopes, the maps of individual
surface slopes did not reveal any vertices with differences between
OLZ and HAL treatment after 5% FDR correction. However, these
seemingly contradictory findings imply that hippocampal regions
affected are likely non-specific, and potentially vary between indi-
viduals. If antipsychotic treatment affects different surface vertices
in different individuals, it would be difficult to detect a region of
consistent slope differences in OLZ vs. HAL. This is supported by
visual observation of individual subjects’ hippocampal surfaces,
which showed considerable within-group variability in the surface
locations of negative slopes. A difference in the number of large
magnitude negative slopes between OLZ and HAL groups indi-
cates that there is however an overall differential treatment effect.
Future studies would be required to assess whether underlying
patient specific factors that may influence hippocampal response
(e.g., substance use, underlying medical conditions, genetic risk
factors, or specific clinical phenotypes) result in differential treat-
ment effects of antipsychotics on hippocampal structure. Such
patient data were not available for this study. Our study also
had slightly more females in the control group, compared to the
psychotic group, although controlling for gender did not sig-
nificantly affect baseline hippocampal differences in our study
(Gur et al., 1991; Murphy et al., 1996). This would not how-
ever influence the primary results of our studies comparing OLZ
and HAL as these groups did not differ significantly by gen-
der. Our results may also have been affected by measurement
variability from the multiple scanners used. However rigorous
quality control efforts where applied to establish reliability of scan-
ner measurements, which would minimize such effects (Styner
et al., 2002). Furthermore, allocation to treatment group occurred
randomly across sites; thus any potential site effects would be
expected to equally affect both treatment groups. Hippocam-
pal shape change may also have been influenced by longitudinal
changes in clinical symptoms, such as psychosis, depression, anxi-
ety, or cognitive abnormalities. Structural findings may thus have
been in part driven by differences in response rates between the
two treatment groups. However these clinical measures were not
available for the current study, thus the relationships were not
investigated.
In summary, compared to the hippocampus of patients treated
with OLZ, those of patients treated with HAL had a larger pro-
portion of large magnitude negative slopes, indicating greater
contraction of a certain portion of their surfaces over time. Fur-
ther studies will be required to evaluate the significance of these
hippocampal regions in the pathogenesis and pathophysiology of
schizophrenia and the relationship between the magnitude of sur-
face contraction and clinical or cognitive changes in patients with
psychotic disorders.
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